CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium.

被引：0
|
作者：
Margolin, KA
Longmate, J
Baratta, T
Synold, T
Weber, J
Gajewski, T
Quirt, I
Christensen, S
Doroshow, JH
机构：
[1] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA
[2] Univ Chicago, Sch Med, Chicago, IL 60637 USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页码：715S / 715S
页数：1
相关论文
共 50 条
  • [41] A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
    Fujisaka, Yasuhito
    Yamada, Yasuhide
    Yamamoto, Noboru
    Horiike, Atsushi
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 732 - 738
  • [42] A randomized phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction therapy
    Pandya, K
    Levy, D
    Hidalgo, M
    Cohen, R
    Lee, M
    Dancey, J
    Schiller, J
    Johnson, D
    LUNG CANCER, 2005, 49 : S54 - S54
  • [43] Anti-tumor activity of single-agent CCI-779 for relapsed mantle cell lymphoma: A phase II trial in the north central cancer treatment group.
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kaufmann, S
    Kurtin, P
    Colgan, J
    Morice, W
    Alberts, S
    Salim, M
    Rowland, K
    Dakhil, S
    Morton, R
    Stella, P
    BLOOD, 2004, 104 (11) : 40A - 40A
  • [44] CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model
    Thallinger, C.
    Poeppl, W.
    Pratscher, B.
    Mayerhofer, M.
    Valent, P.
    Tappeiner, G.
    Joukhadar, C.
    PHARMACOLOGY, 2007, 79 (04) : 207 - 213
  • [45] Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
    Tinker, A. V.
    Ellard, S.
    Welch, S.
    Moens, F.
    Allo, G.
    Tsao, M. S.
    Squire, J.
    Tu, D.
    Eisenhauer, E. A.
    MacKay, H.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (02) : 269 - 274
  • [46] A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor.
    Hidalgo, M
    Rowinsky, E
    Erlichman, C
    Drengler, R
    Marshall, B
    Marks, R
    Edwards, T
    Boni, J
    Dukart, G
    Buckner, J
    ANNALS OF ONCOLOGY, 2000, 11 : 133 - 133
  • [47] PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Chang, Susan
    Kuhn, John
    Lamborn, Kathleen
    Robins, H. Ian
    Yung, Alfred
    Gilbert, Mark R.
    Cloughesy, Timothy
    Lieberman, Frank
    DeAngelis, Lisa
    Abrey, Lauren
    Drappatz, Jan
    Kesari, Santosh
    Dancey, Janet
    Prados, Michel D.
    NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
  • [48] Final results of a phase 2 study of single-agent CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxane regimens
    Chan, S
    Scheulen, ME
    Johnston, S
    Mross, K
    Piccart, M
    Hess, D
    Bouxin, N
    Azli, N
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S82 - S82
  • [49] A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS).
    Okuno, S. H.
    Mahoney, M. R.
    Bailey, H. H.
    Adkins, D. R.
    Maples, W. J.
    Ettinger, D.
    Fitch, T. R.
    Bot, B. M.
    Erlichman, C. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 521S - 521S
  • [50] Randomized 3-arm, phase 2 study of ternsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer.
    Carpenter, JT
    Roché, H
    Campone, M
    Colomer, R
    Jagiello-Gruszfeld, A
    Moore, L
    D'Amore, M
    Kong, S
    Boni, J
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 19S - 19S
12345